Oncogenic Ras/Src cooperativity in pancreatic neoplasia
Open accessThe DOI matches its Crossref record; 11 of the 11 references it cites were found in a registry or an index.
Abstract
Pancreas cancer is one of the most lethal malignancies and is characterized by activating mutations of Kras, present in 95% of patients. More than 60% of pancreatic cancers also display increased c-Src activity, which is associated with poor prognosis. Although loss of tumor suppressor function (for example, p16, p53, Smad4) combined with oncogenic Kras signaling has been shown to accelerate pancreatic duct carcinogenesis, it is unclear whether elevated Src activity contributes to Kras-dependent tumorigenesis or is simply a biomarker of disease progression. Here, we demonstrate that in the context of oncogenic Kras, activation of c-Src through deletion of C-terminal Src kinase (CSK) results in the development of invasive pancreatic ductal adenocarcinoma (PDA) by 5–8 weeks. In contrast, deletion of CSK alone fails to induce neoplasia, while oncogenic Kras expression yields PDA at low frequency after a latency of 12 months. Analysis of cell lines derived from Ras/Src-induced PDA's indicates that oncogenic Ras/Src cooperativity may lead to genomic instability, yet Ras/Src-driven tumor cells remain dependent on Src signaling and as such, Src inhibition suppresses growth of Ras/Src-driven tumors. These findings demonstrate that oncogenic Ras/Src cooperate to accelerate PDA onset and support further studies of Src-directed therapies in pancreatic cancer.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Preinvasive and invasive ductal pancreatic cancer and its early detection in the mouse
Hingorani, S. R., Petricoin, E. F., Maitra, A., Rajapakse, V., King, C., Jacobetz, M. A., Ross, S., Conrads, T. P., Veenstra, T. D., Hitt, B. A., et al. (2003) · Cancer Cell · doi:10.1016/s1535-6108(03)00309-x · Cited by 2,471
Self-citationDNA related to the transforming gene(s) of avian sarcoma viruses is present in normal avian DNA
STEHELIN, D., VARMUS, H. E., BISHOP, J. M., & VOGT, P. K. (1976) · Nature · doi:10.1038/260170a0 · Cited by 1,321 · cited 1×
“Subsequently, the cellular counterpart, c-Src was characterized as the founding member of the Src family of protein tyrosine kinases (SFKs) (Stehelin et al., 1976; Hunter and Sefton, 1980).”
BackgroundHruban, R. H., Takaori, K., Klimstra, D. S., Adsay, N. V., Albores-Saavedra, J., Biankin, A. V., Biankin, S. A., Compton, C., Fukushima, N., Furukawa, T., et al. (2004) · American Journal of Surgical Pathology · doi:10.1097/01.pas.0000126675.59108.80 · Cited by 1,091
A SARCOMA OF THE FOWL TRANSMISSIBLE BY AN AGENT SEPARABLE FROM THE TUMOR CELLS
Rous, P. (1911) · Journal of Experimental Medicine · doi:10.1084/jem.13.4.397 · Cited by 1,051
Aguirre, A. J., Bardeesy, N., Sinha, M., Lopez, L., Tuveson, D. A., Horner, J., Redston, M. S., & DePinho, R. A. (2003) · Genes & Development · doi:10.1101/gad.1158703 · Cited by 1,033 · cited 3×
“Pancreatic tumor cell lines PDA cell lines were isolated as described (Aguirre et al., 2003) from primary tumors in the Kras/Src model.”
BackgroundMethodBardeesy, N., Cheng, K.-H., Berger, J. H., Chu, G. C., Pahler, J., Olson, P., Hezel, A. F., Horner, J., Lauwers, G. Y., Hanahan, D., et al. (2006) · Genes & Development · doi:10.1101/gad.1478706 · Cited by 674 · cited 1×
“Previous studies have documented that loss of tumor suppressors such as p16, p53, Smad4 or TGFbeta receptor 2, dramatically accelerates the development of Kras-dependent PDA in mice (Aguirre et al., 2003; Hingorani et al., 2005; Bardeesy et al., 2006; Ijichi et al., 2006; Izeradjene et al., 2007).”
Backgroundc-Src and cooperating partners in human cancer
Ishizawar, R., & Parsons, S. J. (2004) · Cancer Cell · doi:10.1016/j.ccr.2004.09.001 · Cited by 617
Increase in activity and level of pp60c-src in progressive stages of human colorectal cancer.
Talamonti, M. S., Roh, M. S., Curley, S. A., & Gallick, G. E. (1993) · Journal of Clinical Investigation · doi:10.1172/jci116200 · Cited by 399
Izeradjene, K., Combs, C., Best, M., Gopinathan, A., Wagner, A., Grady, W. M., Deng, C.-X., Hruban, R. H., Adsay, N. V., Tuveson, D. A., et al. (2007) · Cancer Cell · doi:10.1016/j.ccr.2007.01.017 · Cited by 379 · cited 1×
“Previous studies have documented that loss of tumor suppressors such as p16, p53, Smad4 or TGFbeta receptor 2, dramatically accelerates the development of Kras-dependent PDA in mice (Aguirre et al., 2003; Hingorani et al., 2005; Bardeesy et al., 2006; Ijichi et al., 2006; Izeradjene et al., 2007).”
BackgroundGenetic progression in the pancreatic ducts
Hruban, R. H., Wilentz, R. E., & Kern, S. E. (2000) · The American Journal of Pathology · doi:10.1016/s0002-9440(10)65054-7 · Cited by 373 · cited 2×
“In fact, members of the epidermal growth factor receptor family are overexpressed in up to 70% of PDA’s (Hall et al., 1990), and upregulation of ErbB-2 is believed to be one of the earliest events in neoplastic conversion of the pancreas (Hruban et al., 2000).”
BackgroundAn integrin αvβ3–c-Src oncogenic unit promotes anchorage-independence and tumor progression
Desgrosellier, J. S., Barnes, L. A., Shields, D. J., Huang, M., Lau, S. K., Prévost, N., Tarin, D., Shattil, S. J., & Cheresh, D. A. (2009) · Nature Medicine · doi:10.1038/nm.2009 · Cited by 293 · cited 2×
“…epidermal growth factor receptor, RON, IGF-1R and c-Met, as well as the chemokine receptor, CXCR4 and integrins such as avb3, each of which have been implicated in carcinogenesis (Barton et al., 1991; Billadeau et al., 2006; Thomas et al., 2007; Desgrosellier et al., 2009; Ricono et al., 2009).”
BackgroundSelf-citation
Cited by
Allen-Petersen, B. L., Risom, T., Feng, Z., Wang, Z., Jenny, Z. P., Thoma, M. C., Pelz, K. R., Morton, J. P., Sansom, O. J., Lopez, C. D., et al. (2019) · Cancer Research · doi:10.1158/0008-5472.can-18-0717 · Cited by 85
KRas, ROS and the initiation of pancreatic cancer
Storz, P. (2017) · Small GTPases · doi:10.1080/21541248.2016.1192714 · Cited by 82
New structural and functional insight into the regulation of Ras
Kano, Y., Cook, J. D., Lee, J. E., & Ohh, M. (2016) · Seminars in Cell & Developmental Biology · doi:10.1016/j.semcdb.2016.06.006 · Cited by 38
Rao, G., Kim, I.-K., Conforti, F., Liu, J., Zhang, Y.-W., & Giaccone, G. (2018) · European Journal of Cancer · doi:10.1016/j.ejca.2018.05.013 · Cited by 34
Saturno, G., Lopes, F., Niculescu-Duvaz, I., Niculescu-Duvaz, D., Zambon, A., Davies, L., Johnson, L., Preece, N., Lee, R., Viros, A., et al. (2021) · Annals of Oncology · doi:10.1016/j.annonc.2020.10.483 · Cited by 21
“Accordingly, SRC inhibitors cooperate with drugs that target the EGFR/RAS pathway.(26,30,31) Our findings that CCT3833 inhibits the growth of KRASdriven murine PDAC in vitro, and in vivo, are aligned to the literature, validating SRC as a therapeutic target in PDAC, where its overexpression or hyperactivation are mark…”
Background
Metadata
- Authors
- Shields, D. J., Murphy, E. A., Desgrosellier, J. S., Mielgo, A., Lau, S. K. M., Barnes, L. A., Lesperance, J., Huang, M., Schmedt, C., Tarin, D., Lowy, A. M., & Cheresh, D. A.
- Venue
- Oncogene
- Published
- 2011-01-17
- Volume
- 30
- Issue
- 18
- Pages
- 2123-2134
- ISSN
- 0950-9232 (ISSN-L)
- 1476-5594
- OpenAlex
- W2052814975
- Cited by
- 64
- References
- 11
- FWCI
- 3.03
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.